Introduction 1
Tumorigenesis is driven by a series of genetic mutations that promote cancer phenotypes and 2 consequently experience positive selection (Yates & Campbell 2012) . The systematic discovery of 3 such driver mutations, and the genes whose functions they alter, has been made possible by tumour impediment in both cases has been the lack of true-positive set of known lncRNA driver genes, To facilitate the future discovery of cancer lncRNAs, and gain insights into their biology, we 28 have compiled a highly-curated set of cases with roles in cancer processes. Here we present the 29 Cancer LncRNA Census (CLC), the first compendium of lncRNAs with direct functional or genetic 30 evidence for cancer roles. We demonstrate the utility of CLC in assessing the performance of driver 31 lncRNA predictions. Through analysis of this geneset, we demonstrate that cancer lncRNAs have a 32 unique series of features that may in future be used to assist de novo predictions. Finally, we show 33 that CLC genes have conserved cancer roles across the approximately 80 million years of evolution 1 separating humans and rodents. 2 cancer functionality, or is simply a result of their being amongst the most early-discovered and 1 widely-studied lncRNAs. 2 In vitro experiments were the most frequent evidence source, usually consisting of RNAi-3 mediated knockdown in cultured cell lines, coupled to phenotypic assays such as proliferation or 4 migration ( Supplementary Figure 1) . Far fewer have been studied in vivo, or have cancer-associated 5 somatic or germline mutations. 19 lncRNAs had 3 or more independent evidence sources 6 ( Supplementary Figure 1) . 7 8 CLC and other databases 9 There are a number of relevant lncRNA databases presently available: the Lnc2Cancer database 10 (n= 654) (Ning et al. 2016) , the LncRNADisease Database (n=121) (Chen et al. 2013) , lncRNAdb 11 (n=191) (Quek et al. 2015) and the "Cancer Related LncRNAs" set we recently produced (n=45) 12 (Lanzós et al. 2017) . CLC covers between 17% and 31% of these databases (Lnc2Cancer and 13 LncRNADisease respectively) but none of these resources contain the complete list of genes presented 14 here (Figure 2A ). We sought to use recent unbiased proliferation screen data to independently 15 compare cancer lncRNA databases (Zhu et al. 2016; Liu et al. 2017 ). Using only annotated genes, CLC is the resource that overall has the highest fraction of independently-identified 17 proliferation lncRNAs, although the sparse nature of the data means that this conclusion is not 18 definitive ( Figure 2B ). 19 20 CLC for benchmarking lncRNA driver prediction methods 21 One of the primary motivations for CLC is to develop a true positive set for benchmarking and 22 comparing methods for identifying driver lncRNAs. In the domain of protein-coding driver gene 23 predictions, the Cancer Gene Census (CGC) has become such a "gold standard" training set (Futreal 24 et al. 2004) . Typically, the predicted driver genes belonging to CGC are judged to be true positives, 25 and the fraction of these amongst predictions is used to estimate the Positive Predictive Value (PPV), 26 or precision. This measure can be calculated for increasing cutoff levels, to assess the optimal cutoff. 27 First, we used CLC to examine the performance of the lncRNA driver predictor ExInAtor 28 (Lanzós et al. 2017) in recalling CLC genes using PCAWG tumour mutation data (PCAWG 29 Consortium, Manuscript In Preparation). A total of 2,687 GENCODE lncRNAs were tested here, of 30 which 82 (3.1%) belong to CLC. Driver predictions on several cancers at the standard False Discovery 31 Rate ("q-value") cutoff of 0.1 are shown for selected cancers in Figure 3A . That panel shows the 32 CLC-defined precision (y-axis) as a function of predicted driver genes ranked by q-value (x-axis). We 33 observe rather heterogeneous performance across cancer cohorts. This may reflect a combination of intrinsic biological differences and differences in cohort sizes, which differs widely between the 1 datasets shown. For the merged pan-cancer dataset, ExInAtor predicted three CLC genes amongst its 2 top ten candidates (q-value < 0.1), a rate far in excess of the background expectation ("Baseline", 3 being the fraction all lncRNAs being in CLC). Similar enrichments are observed for other cancer 4 types. These results support both the predictive value of ExInAtor, and the usefulness of CLC in 5 assessing lncRNA driver predictors. Comprehensive CLC-based assessments of lncRNA driver 6 discovery, across all methods and tumour cohorts in PCAWG, may be found in the main PCAWG 7 driver prediction publication (PCAWG Consortium, Manuscript In Preparation) . 8 Finally, we assessed the precision (i.e. positive predictive value) of PCAWG lncRNA and 9 protein-coding driver predictions across all cancers and all prediction methods (PCAWG Consortium, 10 Manuscript In Preparation). Using the same q-value cutoff of 0.1, we found that across all cancer 11 types and methods, a total of 8 (8.5%) of lncRNA predictions belong to CLC ( Figure 3B ), while a 12 total of 139 (23.1%) of protein-coding predictions belong to CGC ( Figure 3C ). In terms of sensitivity, 13 9.8% and 25.1% of CLC and CGC genes are predicted as candidates, respectively. Despite the lower 14 detection of CLC genes in comparison to CGC genes, both sensitivity rates significantly exceed the 15 prediction rate of nonCLC and nonCGC genes (P=0.007 and P<0.001 Fisher's exact tests, 16 respectively), again highlighting the usefulness of the CLC geneset ( Figure 3C ). 17 18 CLC genes are distinguished by function-and disease-related features 19 We recently found evidence, using a smaller set of Cancer Related LncRNAs (CRLs), that cancer 20 lncRNAs are distinguished by various genomic and expression features indicative of biological 21 function (Lanzós et al. 2017) . We here extended these findings using a large series of potential gene 22 features, to search for those features distinguishing CLC from nonCLC lncRNAs ( Figure 4A ).
23
First, associations with expected cancer-related features were tested ( Figure 4B ). CLC genes are 24 significantly more likely to have their transcription start site (TSS) within 100 kb of cancer-associated 25 germline SNPs ("Cancer SNPs 100kb TSS"), and more likely to be either differentially-expressed or 26 epigenetically-silenced in tumours (Yan et al. 2015) ( Figure 4B ). Intriguingly, we observed a 27 tendency for CLC lncRNAs to be more likely to lie within 1 kb of known cancer protein-coding genes 28 ("CGC 1kb TSS") -this is explored in more detail below. Furthermore, we found that CLC genes are 29 also significantly closer to non-cancer, phenotype-associated germline SNPs ("NonCancer SNPs 30 100kb TSS") in comparison to nonCLC genes ( Figure 4B ), supporting the biological functionality of 31 CLC genes. 32 We next investigated the properties of the genes themselves. As seen in Figure 4C , and consistent 33 with our previous findings (Lanzós et al. 2017), CLC genes ("Gene length") and their spliced products ("Exonic length") are significantly longer than average. No difference was observed in the ratio of 1 exonic to total length ("Exonic content"), nor overall exon repetitive sequence coverage ("Repeats 2 coverage"), nor GC content.
3 CLC genes also tend to have greater evidence of function, as inferred from evolutionary 4 conservation. Base-level conservation at various evolutionary depths was calculated for lncRNA 5 exons and promoters ( Figure 4D ). Across all measures tested, using either average base-level scores 6 or percent coverage by conserved elements, we found that CLC genes' exons are significantly more 7 conserved than other lncRNAs ( Figure 4D ). The same was observed for conservation of promoter 8 regions.
9
High levels of gene expression in normal tissues are known to correlate with lncRNA 10 conservation, and are hypothesized to be a reflection of functionality (Managadze et al. 2011). 11 Additionally, genes with oncogenic roles tend to be highly expressed in cancer samples (Furney et al. 12 2006). We found that CLC has consistently higher steady-state expression levels across PCAWG 13 tumours ( Figure 4E ), as well as healthy organs and cultured cell lines (Supplementary Figure 2) . 14 Finally, we investigated whether CLC transcripts might be initiated by any types of Transposable 15 Elements (TEs) (see Materials and methods). We found that CLC TSSs are enriched for one category, Evidence for genomic clustering of non-coding and protein-coding cancer genes 19 In light of recent evidence for colocalisation and coexpression of disease-related lncRNAs and 20 protein-coding genes (Tan et al. 2017), we were curious whether such an effect holds for cancer-21 related lncRNAs and protein-coding genes. We asked, more specifically, whether CLC genes tend to 22 be closer to CGC genes than expected by chance, and whether this is manifested in a more co-23 regulated expression.
24
To this aim, we computed TSS-TSS distances from lncRNAs to protein-coding genes and we 25 found that CLC genes on average tend to lie moderately closer to protein-coding genes of all types, 26 compared to nonCLC lncRNAs (Supplementary Figure 4A , B). Since CLC genes are enriched for 27 functional features (i.e. expression and conservation), we couldn't rule out the possibility that 28 proximity to protein-coding genes is a feature of functional lncRNAs rather than cancer lncRNA 29 genes. In order to further investigate this possibility, we repeated the analysis dividing the nonCLC 30 set into potentially functional nonCLC genes (PF-nonCLC) (nonCLC genes sampled to match CLC 31 expression and conservation, N=149, Supplementary Figure 5 ) and "other nonCLC" (the rest of 32 nonCLC). Interestingly, when comparing distances to any type of protein-coding genes, both CLC 33 and PF-nonCLC are significantly closer than the rest of lncRNA (Wilcoxon test, P=0.03, 0.007, respectively), being the PF-nonCLC genes the closest ones (median 21.9 kb, 29 kb and 37.8 kb, for 1 PF-nonCLC, CLC, and other nonCLC, respectively) (Supplementary Figure 4C ). However, when 2 assessing specifically for distance to CGC genes, only CLC set is significantly closer than the rest of 3 lncRNAs (Wilcoxon test, P=0.0008) and it represents the group with the lowest distance (median 4 1,122 kb, 1,330kb and 1,607 kb for CLC, PF-nonCLC, and other nonCLC, respectively) ( Figure 5A ).
5
Thus, although proximity to protein-coding genes seems to be a feature of potentially functional 6 lncRNAs, CLC genes are closer to cancer genes compared to other lncRNAs with similar function-7 like properties.
8
It has been widely proposed that proximal lncRNA / protein-coding gene pairs are involved in 9 cis-regulatory relationships, which is reflected in expression correlation (Ponjavic et al. 2009 ). We 10 next asked whether proximal CLC-CGC pairs exhibit this behaviour. An important potential 11 confounding factor, is the known positive correlation between nearby gene pairs (Marques et al.
12
2013), and this must be controlled for. Using gene expression data across 11 human cell lines, we 13 observed a positive correlation between CLC-CGC gene pairs for each cell type ( Figure 5B ). To 14 control for the effect of proximity on correlation, we next randomly sampled a similar number of non-15 CLC lncRNAs with matched distances (TSS-TSS) from the same CGC genes, and found that this 16 correlation was lost ( Figure 5B , "nonCLC-CGC"). To further control for a possible correlation arising 17 from the simple fact that both CGC and CLC genes are involved in cancer, and CLC genes are in 18 general enriched for conservation and expression, we next randomly shuffled the CLC-CGC pairs 19 1000 times, again observing no correlation ( Figure 5B , "Shuffled CLC-CGC"). Together these results
20
show that genomically-proximal protein-coding/non-coding gene pairs exhibit an expression 21 correlation that exceeds that expected by chance, even when controlling for genomic distance.
22
These results prompted us to further explore the genomic localization of CLC genes relative to 23 their proximal protein-coding gene and the nature of their neighbouring genes. Next, we observed an 24 unexpected difference in the genomic organisation of CLC genes: when classified by orientation with 25 respect to nearest protein-coding gene (Derrien et al. 2012), we found a significant enrichment of 26 CLC genes immediately downstream and on the same strand as protein-coding genes ("Samestrand, 27 pc up", Figure 5C ). Moreover, CLC genes are approximately twice as likely to lie in an upstream, 28 divergent orientation to a protein-coding gene ("Divergent", Figure 5C ). Of these CLC genes, 20% 29 are divergent to a CGC gene, compared to 5% for nonCLC genes (P=0.018, Fisher's exact test) 30 ( Figure 5D ), and several are divergent to protein-coding genes that have also been linked or defined 31 to be involved in cancer, despite not being classified as CGCs ( Supplementary Table 2 ).
32
Given this noteworthy enrichment of CGC genes in a divergent configuration to protein-coding 33 genes, we next inspected the latters' function annotation. Examining their Gene Ontology (GO) terms, molecular pathways and other gene function related terms, we found this group of genes to be 1 enriched in GO terms for "sequence-specific DNA binding", "DNA binding", "tube development" 2 and "transcriptional misregulation in cancer" ( Figure 5E ). These results were confirmed by another, 3 independent GO-analysis suite (see Materials and Methods). Interestingly, three out of the top four 4 functional groups were observed previously in a study of protein-coding genes divergent to long 5 upstream antisense transcripts in primary mouse tissues (Lepoivre et al. 2013 ).
6
Thus, CLC genes appear to be non-randomly distributed with respect to protein-coding genes, 7 and particularly their CGC subset. Evidence for anciently conserved cancer roles of lncRNAs 10 In mouse, numerous studies have employed unbiased forward genetic screens to identify genes 11 that either inhibit or promote tumorigenesis (Copeland & Jenkins 2010) . These studies use 12 engineered, randomly-integrating transposons carrying bidirectional polyadenylation sites as well as 13 strong promoters. Insertions, or clusters of insertions, called "common insertion sites" (CIS) that are 14 identified in sequenced tumour DNA, implicate the overlapping or neighbouring gene locus as either 15 an oncogene or tumour-suppressor gene. Although these studies have traditionally been focused on 16 identifying protein-coding genes, they can in principle also identify non-coding RNA driver loci. 17 We thus reasoned that comparison of mouse CISs to orthologous human regions could yield 18 independent evidence for the functionality of human cancer lncRNAs ( Figure 6A ). To test this, we Table 4 ). These sites were then mapped to orthologous regions 21 in the human genome, resulting in 1,309 human CISs, or hCISs. 7.3% of these CISs lie outside of 22 protein-coding gene boundaries, and were used for the following analyses.
23
Mapping hCISs to lncRNA annotations, we discovered altogether eight CLC genes (6.6%) 24 carrying at least one insertion within their gene span: DLEU2, GAS5, MONC, NEAT1, PINT, PVT1, 25 SLNCR1, XIST (Table 1) . In contrast, just 61 (0.4%) nonCLC genes contained hCISs ( Figure 6B ). A 26 good example is SLINCR1, shown in Figure 6C , which drives invasiveness of human melanoma cells 27 (Schmidt et al. 2016), and whose mouse orthologue contains a CIS discovered in pancreatic cancer. 28 We examined the possibility that hCIS insertions in these CLC genes could in fact be caused by 29 nearby, protein-coding cancer genes. However, none of these eight CLC genes are within 100 kb of 30 a CGC gene, with the exception of CCAT1 lncRNA, lying 58 kb from c-MYC oncogene.
31
This analysis would suggest that CLC genes are enriched for hCISs; however, there remains the 32 possibility that this is confounded by their greater length. To account for this, we performed two 33 separate validations. First, sets of nonCLC genes with CLC-matched length were randomly sampled, and the number of intersecting hCISs per unit gene length (Mb) was counted ( Supplementary Figure   1 6A). Second, CLC genes were randomly relocated in the genome, and the number of genes 2 intersecting at least one hCIS was counted (Supplementary Figure 6B ). Both analyses showed that 3 the number of intersecting hCISs per Mb of CLC gene span is far greater than expected. In contrast, 4 nonCLC genes show a depletion for hCIS sites (Supplementary Figure 6C) . 5 We further compared the enrichment of hCIS in protein-coding genes, lncRNA genes and other 6 intergenic space. Compared to the genomic space they occupy, there is a clear enrichment of hCIS 7 elements in both protein-coding CGC genes, as well as CLC lncRNAs ( Figure 6D ). Expressed as 8 insertion rate per megabase of gene span, it is clear that CLC genes are targeted more frequently than 9 background intergenic DNA and non-cancer-related protein-coding genes. Of note are the non-10 background insertion rates for non-cancer-related protein-coding and lncRNA genes, suggesting that 11 there remain substantial numbers of undiscovered cancer genes in both groups.
12
Together these analyses demonstrate that CLC genes are orthologous to mouse cancer-causing 13 genomic loci at a rate greater than expected by random chance. These identified cases, and possibly 14 other CLC genes, display cancer functions that have been conserved over tens of millions of years Discussion 1 We have presented the Cancer LncRNA Census, the first controlled set of GENCODE-annotated 2 lncRNAs with demonstrated roles in tumorigenesis or cancer phenotypes.
3
The present state of knowledge of lncRNAs in cancer, and indeed lncRNAs generally, remains 4 highly incomplete. Consequently, our aim was to create a geneset with the greatest possible 5 confidence, by eliminating the relatively large number of published "cancer lncRNAs" with as-yet 6 unproven causative roles in disease processes. Thus, we used a rather strict definition of cancer 7 lncRNA, being those having direct experimental or genetic evidence for a causative role in cancer 8 phenotypes. By this measure, gene expression changes alone do not suffice. By introducing these 9 well-defined inclusion criteria, we hope to ensure that CLC contains the highest possible proportion 10 of bona fide cancer genes, giving it maximum utility for de novo predictor benchmarking. In addition, 11 its basis in GENCODE ensures portability across datasets and projects. Inevitably some well-known 12 lncRNAs did not meet these criteria (including SRA1, CONCR, KCNQ1OT1) (Marchese et al. 2016; 13 Lanz et al. 1999; Higashimoto et al. 2006 ); these may be included in future when more validation 14 data becomes available. We believe that CLC will complement the established lncRNA databases 15 such as lncRNAdb, LncRNADisease and Lnc2Cancer, which are more comprehensive, but are likely 
18
De novo lncRNA driver gene discovery is likely to become increasingly important as the number 19 of sequenced tumours grow. The creation and refinement of statistical methods for driver gene 20 discovery will depend on the available of high-quality true positive genesets such as CLC. It will be 21 important to continue to maintain and improve the CLC in step with anticipated growth in cell lines, which will be incorporated in future versions. 25 We used CLC to estimate the performance of de novo driver lncRNA predictions from the 26 PCAWG project, made using the ExInAtor pipeline (Lanzós et al. 2017) . Supporting the usefulness 27 of this approach, we found an enrichment for CLC genes amongst the top-ranked driver predictions.
28
Extending this to the full set of PCAWG driver predictors, approximately ten percent of CLC genes 29 (9.8%) are called as drivers by at least one method (PCAWG Consortium, Manuscript In Preparation), 30 which is lower to the rate of CGC genes identified (25.1%).
31
The low rate of concordance between de novo predictions and CLC genes may be due to 32 technical or biological factors. Indeed, it is important to state that we do not yet know whether CLC 33 play two distinct roles in cancer: first, as driver genes, defined as those whose mutations are early and 1 positively-selected events in tumorigenesis; or second, as "downstream genes", which do make a 2 genuine contribution to cancer phenotypes, but through non-genetic alterations in cellular networks 3 resulting from changes in expression, localisation or molecular interactions. These downstream genes 4 may not display positively-selected mutational patterns, but would be expected to display cancer-5 specific alterations in expression. A key question for the future is how lncRNAs break down between 6 these two categories, and the utility of CLC in benchmarking de novo driver predictions will depend 7 on this. However, the identification of lncRNAs whose silencing or overexpression is sufficient for 8 tumour formation in mouse, would seem to suggest that they are true "driver genes". proximal and exhibit elevated expression correlation. This points to a regulatory link between cancer 18 lncRNAs and protein-coding genes, perhaps through chromatin looping, as described in previous 19 reports for CCAT1 and MYC, for example (Xiang et al. 2014 ).
20
One important caveat for all features discussed here is ascertainment bias: almost all lncRNAs 21 discussed have been curated from published, single-gene studies. It is entirely possible that selection 22 of genes for initial studies was highly non-random, and influenced by a number of factors -including 23 high expression, evolutionary conservation and proximity to known cancer genes -that could bias 24 our inference of lncRNA features. This may be the explanation for the observed excess of cancer 25 lncRNAs in divergent configuration to protein-coding genes. However, the general validity of some 26 of the CLC-specific features described here -including high expression and evolutionary Despite the relatively low concordance of CLC genes with PCAWG driver predictions, the 30 results of this study strongly support the value and key cancer role of identified lncRNAs in cancer.
31
Most notably, the existence of a core set of eight lncRNAs with independently-identified mouse 32 orthologues with similar cancer functions, is a powerful evidence that these genes are bona fide cancer 33 genes, whose overexpression or silencing can drive tumour formation. To our knowledge this is the most direct demonstration to date of anciently-conserved functions and disease roles for lncRNAs. It 1 will be intriguing to investigate in future whether more human-mouse orthologous lncRNAs have 2 been identified in such screens. in Pubmed. If publications were found conforming to at least one of the inclusion criteria (below) and 8 the gene has a GENCODE ID, then it was added to CLC, with appropriate information on the 9 associated cancer, biological activity. For the numerous cases where no GENCODE ID was supplied 10 in the original publication, any available ID, or primer or siRNA sequence was used to identify the 11 gene using the UCSC Genome Browser Blat tool (Kent et al. 2002) .
12
Inclusion criteria sufficient to define a cancer lncRNA and link it to a cancer type were: 
25
If an lncRNA was found to promote tumorigenesis or cancer phenotype, it was defined as 26 "oncogene" (og). Conversely those found to inhibit such phenotypes were defined as "tumour 27 suppressor" (tsg). Several lncRNAs were found to have both activities recorded in different cancer 28 types, and were given both labels (og/tsg). For every lncRNA-cancer association, a single 29 representative publication is recorded. Finally, it is important to note that no lncRNAs were included 30 based on evidence from previous driver gene discovery studies of the types represented by 
33
CLC set at this stage relies on GENCODE v24 annotation, and therefore all CLC genes have a 1 GENCODE v24 ID assigned. However, data relative to GENCODE v24 was not available for all 2 types of data and analysis used in this study (ie all data relative to PCAWG is based on GENCODE 3 v19). Thus, for some analysis only genes also present in GENCODE v19 could be used (specified in 4 the corresponding methods section) and the total number of genes analysed in these cases is slightly 5 lower (107 instead of 122 CLC genes and 13,503 instead of 15,827 nonCLC). 
Feature Identification

21
We compiled several quantitative and qualitative traits of GENCODE lncRNAs and used them 22 to compare CLC genes to the rest of lncRNAs (referred to as "nonCLC"). Analysis of quantitative 23 traits were performed using Wilcoxon test while qualitative traits were tested using Fisher' exact test.
24
These methods principally refer to Figure 4 and 5 as well as Supplementary Figures 2, 3, 4 and 5.
25
Cancer SNPs: On October, 4, 2016, we collected all 2,192 SNPs related to "cancer", "tumour" In Preparation). In this last case, for each cancer type we computed the expression mean of genes 24 across all RNAseq samples belonging to that cancer type (GENCODE v19).
Transposable elements: We downloaded 5,520,016 transposable elements from the UCSC matching the same TSS-TSS distance distribution as above, and performed the same expression 14 correlation analysis ("nonCLC-CGC"). Finally, to further control for the fact that CLC and CGC are 15 both cancer genes, which may influence their expression correlation, we shuffled CLC-CGC pairs 16 1000 times, and tested expression correlation for each set ("Shuffled CLC-CGC").
17
Genomic classification: We used an in-house script to classify lncRNA transcripts into different 18 genomic categories based on their orientation and proximity to the closest protein-coding gene 19 (GENCODE v24): a 10 kb distance was used to distinguish "genic" from "intergenic" lncRNAs.
20
When transcripts belonging to the same gene had different classifications, we used the category 21 represented by the largest number of transcripts.
22
Functional enrichment analysis: The list of protein-coding genes (GENCODE v24) that are 23 divergent and closer than 10 kb to CLC genes (or nonCLC) was used for a functional enrichment 24 analysis (20 unique genes in the case of CLC analysis and 1202 in the case of nonCLC analysis gene. This is explored in more detail in the next Figure. nonCLC genes that contain human orthologous common insertion sites (hCIS) (see Table 1 ). C a n ce r a ss o ci a te d e p ig e n e tic a lly si le n ce d ln cR N A g e n e s D iff e re n tia lly e xp re ss e d g e n e s C a n ce r S N P s 1 0 kb T S S C a n ce r S N P s 1 0 0 kb T S S N o n ca n ce r S N P s 1 kb T S S C a n ce r S N P s 1 kb T S S 
